Carboplatin as a Radiation Sensitizer in Locally Advanced Cervical Cancer: A Pilot Study

Muderspach, Laila I.; Curtin, John P.; Roman, Lynda D.; Gebhardt, Judith A.; Klement, Vaclav; Qian, Dajun; Morrow, C.Paul; Felix, Janine F.; Formenti, Silvia C.; Fm, Muggia

doi:10.1006/gyno.1997.4647

Cited by 41 publications

(14 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[53][54][55][56][57][58][59] Although cisplatin and carboplatin are often used interchangeably, we cannot assume that the results of our study also apply to treatment with carboplatin.…”

Section: Discussionmentioning

confidence: 99%

Concurrent Cisplatin-Based Radiotherapy and Chemotherapy for Locally Advanced Cervical Cancer

et al. 1999

View full text Add to dashboard Cite

show abstract

“…[53][54][55][56][57][58][59] Although cisplatin and carboplatin are often used interchangeably, we cannot assume that the results of our study also apply to treatment with carboplatin.…”

Section: Discussionmentioning

confidence: 99%

Concurrent Cisplatin-Based Radiotherapy and Chemotherapy for Locally Advanced Cervical Cancer

et al. 1999

View full text Add to dashboard Cite

show abstract

“…We think that the high effect of NRCHT on the tumor at pelvic wall was due to the additional effect of CHT (ifosfamide) and the low irradiation dose of intracavitary BT in this region according to the experiments of Tonkin [16] allowing operation with free surgical margins in 34%. In addition carboplatin probably acted as a radiosensitizer [12] in the whole by BT irradiated region. The presented novel NRCHT-regimen is somewhat different from a schedule using NCHT alone.…”

Section: Discussionmentioning

confidence: 99%

“…Many studies and metaanalyses [7][8][9][10][11] have demonstrated the efficacy of ifosfamide and carboplatin alone or as combination therapy in advanced or recurrent cervical cancer. Additionally, apparent radiosensitization of platin-containing regimens in malignancies have been observed [12][13][14][15]. Experiments with human cervix carcinoma xenografts treated with ifosfamide and brachytherapy (BT) in low-dose rates showed a marked delay of tumor growth [16].…”

Section: Introductionmentioning

confidence: 99%

Neoadjuvant Chemotherapy and Brachytherapy – a New Perspective in the Therapy of Advanced Cervical Carcinoma

Kohler¹,

Weise²,

Breitsprecher³

et al. 1998

Oncol Res Treat

View full text Add to dashboard Cite

“…It has been reported that CBDCA has a radiation-sensitizing effect, 52 and that, compared with CDDP, the drug is associated with less severe nonhematological toxicities, such as nephrotoxicity, gastrointestinal toxicity, and neurotoxicity, although it has comparable antitumor activity. The reduced toxicity, may be advantageous with respect to both treatment compliance and QOL, especially when treating elderly patients and patients with advanced disease, who sometimes develop hydronephrosis.…”

Section: Optimal Dose and Schedule Of Platinummentioning

confidence: 99%

Chemoradiotherapy for uterine cancer: current status and perspectives

Kuzuya

2004

Int J Clin Oncol

View full text Add to dashboard Cite

The conventional local treatment methods (surgery and radiation) for cervical cancer have reached a plateau in terms of survival benefit and, therefore, in this review, new treatment strategies (combined chemotherapy [CT] and local therapy) to overcome the poor prognosis were examined in high-risk groups. The effectiveness of neoadjuvant chemotherapy (NAC) administered prior to radiotherapy (RT) has not been confirmed for any disease stages. But NAC followed by surgery may improve survival in patients with stage Ib2 compared with surgery alone; and in patients with stage Ib2 to IIB compared with RT alone. Five large randomized clinical trials (RCTs) demonstrated a significant survival benefit for patients treated with concurrent chemoradiotherapy (CCRT), using a cisplatin (CDDP)-based regimen, with a 28%-50% relative reduction in the risk of death. In addition, the results of a metaanalysis of 19 RCTs of CCRT (1981-2000) involving 4580 patients showed that CCRT significantly improved overall survival (OS) hazard ratio ([HR] 0.71; P < 0.0001), as well as progression-free survival (PFS; HR 0.61; P < 0.0001). In line with these results, CCRT is currently recommended as standard therapy for advanced cancer (stage III/IVA) in the United States. However, there remains much controversy and uncertainty regarding the optimal therapeutic approaches, especially for patients with advanced cancer. Additional RCTs should be conducted to find the optimal CT regimen and RT for Japanese patients, considering acute and late complications, as well as differences in pelvic anatomy, total radiation dose, and RT procedures between Japan and other countries. Evidence obtained from such studies should establish the optimal CCRT treatment protocol and define the patient population (disease stage) that the protocol really benefits.

show abstract

Carboplatin as a Radiation Sensitizer in Locally Advanced Cervical Cancer: A Pilot Study

Cited by 41 publications

References 16 publications

Concurrent Cisplatin-Based Radiotherapy and Chemotherapy for Locally Advanced Cervical Cancer

Concurrent Cisplatin-Based Radiotherapy and Chemotherapy for Locally Advanced Cervical Cancer

Neoadjuvant Chemotherapy and Brachytherapy – a New Perspective in the Therapy of Advanced Cervical Carcinoma

Chemoradiotherapy for uterine cancer: current status and perspectives

Contact Info

Product

Resources

About